CytomX Therapeutics Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 122

Employees

  • Stock Symbol
  • CTMX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.23
  • (As of Tuesday Closing)

CytomX Therapeutics General Information

Description

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Contact Information

Website
www.cytomx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 151 Oyster Point Boulevard
  • Suite 400
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 151 Oyster Point Boulevard
  • Suite 400
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CytomX Therapeutics Stock Performance

As of 03-Dec-2024, CytomX Therapeutics’s stock price is $1.23. Its current market cap is $96.3M with 78.3M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.23 $1.09 $0.83 - $5.85 $96.3M 78.3M 1.03M $0.16

CytomX Therapeutics Financials Summary

As of 30-Sep-2024, CytomX Therapeutics has a trailing 12-month revenue of $127M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (33,257) (75,222) (69,539) 68,766
Revenue 126,617 101,214 53,163 37,312
EBITDA 8,541 (4,339) (98,552) (113,419)
Net Income 13,830 (569) (99,317) (115,870)
Total Assets 138,981 201,792 260,891 339,411
Total Debt 10,597 13,974 18,057 21,674
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CytomX Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CytomX Therapeutics‘s full profile, request access.

Request a free trial

CytomX Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore CytomX Therapeutics‘s full profile, request access.

Request a free trial

CytomX Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is e
Biotechnology
South San Francisco, CA
122 As of 2023

Cambridge, MA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CytomX Therapeutics Competitors (91)

One of CytomX Therapeutics’s 91 competitors is Mersana Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mersana Therapeutics Formerly VC-backed Cambridge, MA
Aura Biosciences Formerly VC-backed Cambridge, MA
Vor Biopharma Formerly VC-backed Cambridge, MA
Celldex Therapeutics Formerly VC-backed Hampton, NJ
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 91 competitors. Get the full list »

CytomX Therapeutics Patents

CytomX Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230174995-A1 Activatable polypeptide complex Pending 15-Oct-2021
US-20230183382-A1 Activatable polypeptide complex Pending 15-Oct-2021
AU-2022365116-A1 Activatable polypeptide complex Pending 15-Oct-2021
AU-2022367525-A1 Activatable polypeptide complex Pending 15-Oct-2021
CA-3234609-A1 Activatable polypeptide complex Pending 15-Oct-2021 C07K16/2863
To view CytomX Therapeutics’s complete patent history, request access »

CytomX Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CytomX Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CytomX Therapeutics‘s full profile, request access.

Request a free trial

CytomX Therapeutics Investments (1)

CytomX Therapeutics’s most recent deal was a Corporate Asset Purchase with Agensys (Drug conjugate linker-toxin & CD3-based bispecific technologies). The deal was made on 07-Jan-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Agensys (Drug conjugate linker-toxin & CD3-based bispecific technologies) 07-Jan-2019 Corporate Asset Purchase Buildings and Property
To view CytomX Therapeutics’s complete investments history, request access »

CytomX Therapeutics ESG

Risk Overview

Risk Rating

Updated October, 01, 2023

27.28 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,035

Rank

Percentile

Pharmaceuticals

Industry

of 847

Rank

Percentile

Biotechnology

Subindustry

of 367

Rank

Percentile

To view CytomX Therapeutics’s complete esg history, request access »

CytomX Therapeutics FAQs

  • When was CytomX Therapeutics founded?

    CytomX Therapeutics was founded in 2008.

  • Where is CytomX Therapeutics headquartered?

    CytomX Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of CytomX Therapeutics?

    CytomX Therapeutics has 122 total employees.

  • What industry is CytomX Therapeutics in?

    CytomX Therapeutics’s primary industry is Biotechnology.

  • Is CytomX Therapeutics a private or public company?

    CytomX Therapeutics is a Public company.

  • What is CytomX Therapeutics’s stock symbol?

    The ticker symbol for CytomX Therapeutics is CTMX.

  • What is the current stock price of CytomX Therapeutics?

    As of 03-Dec-2024 the stock price of CytomX Therapeutics is $1.23.

  • What is the current market cap of CytomX Therapeutics?

    The current market capitalization of CytomX Therapeutics is $96.3M.

  • What is CytomX Therapeutics’s current revenue?

    The trailing twelve month revenue for CytomX Therapeutics is $127M.

  • Who are CytomX Therapeutics’s competitors?

    Mersana Therapeutics, Aura Biosciences, Vor Biopharma, Celldex Therapeutics, and Inovio Pharmaceuticals are some of the 91 competitors of CytomX Therapeutics.

  • What is CytomX Therapeutics’s annual earnings per share (EPS)?

    CytomX Therapeutics’s EPS for 12 months was $0.16.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »